For example, one preclinical evidence highlighted the effectiveness of combining cisplatin, a widely known chemotherapeutic drug, with the inhibition of CXCR2 axis (104); the authors showed that the agent SB225002, that selectively inhibits CXCR2, enhanced the therapeutic effect of cisplatin in lung cancer mice models, which was associated with a significant reduction of neutrophil infiltration and enhanced CD8+ T cell anti-tumor. Here, CXCR2 is linked to lung carcinoma.